Our Selvita valuation has increased from PLN577m or PLN43/share to PLN1.04bn or PLN75/share mainly due to our substantially revised R&D model. At present we do not include the planned share issue in our model as according to Selvita, the timing and pricing of the issue are dependent on the outcome of the interaction with the FDA regarding the clinical hold placed on the Phase I/II trial with SEL24. We use DCF-based calculations with a discount rate of 10% to value the core drug discovery services business and research collaborations. Separately we use risk-adjusted NPV models with a discount rate of 12.5% for Selvita’s R&D projects in various stages. These projects include allocated R&D costs (based on our assumptions, Exhibit 14), which are excluded from the DCF model to avoid double accounting.
For the R&D pipeline valuation, we have made a number of changes to reflect Selvita’s new strategy for 2017-2022. Previously we valued only Selvita’s lead products SEL24 and SEL120 and the partnering deals with Merck. With the new strategy Selvita has committed to advancing its preclinical pipeline and provided estimated investments needed for each platform. Therefore, the company’s valuation has been rebalanced across the preclinical and clinical pipeline.
Exhibit 11 summarises the stages of the drug discovery process. Selvita has assets across all these stages and over the past few years we believe several of the projects have matured enough to be included in our valuation with SEL24 and SEL120. We have selected those projects that have published data and are identified by the company as core assets. Namely, SMARCA2 and SHMT2 inhibitors and A2A/A2B antagonist.
Exhibit 11: Overview of the drug discovery process
|
|
Source: Edison Investment Research
|
Our valuation and assumptions for the projects are summarised in Exhibits 12, 13 and 14. Due to the early stage of the assets (we assign 2% success probability for the newly added projects) to evaluate market potential we used top-down approach and looked at how benchmark or relevant products are performing in the market. Associated R&D costs are estimated from those Selvita provided with its new strategy. R&D model changes include:
■
R&D expenditure. With its strategy update, Selvita provided R&D cost estimates for the period 2017-2021. For the targeted therapies platform costs are estimated at $13.7m; for cancer metabolism and immunometabolism – $19.3m; for the immunooncology platform – $13.7m. We have split some these costs per products to calculate rNPV values (described in Exhibit 14), but note that we included in our valuation only more advanced projects in the preclinical and clinical stages. Selvita is also working on a number of earlier projects, disclosed and undisclosed, although these are likely less costly. Clinical stage trials should account for the bulk of the R&D spend.
■
SEL24 success probability reduced to 7.5% from 15% to reflect the clinical hold uncertainty. As a result we value SEL24 at PLN5.4/share. If the hold is lifted and we increase the probability back to 15%, the value would be PLN9.2/share.
■
SEL24 deal terms revision. Following the licensing deal with Menarini, we have revised the deal structure in our model for SEL24. As discussed above, the terms were broadly in line in overall value terms with our assumptions, therefore the revision did not have a substantial effect on the rNPV for this project.
■
Licensing deal for SEL120. In line with Selvita’s strategy we postponed the licensing deal until Phase II. This also means that the deal terms should be more favourable than those of Menarini deal, assuming the data are positive. As detailed in Exhibit 12, we use Novartis/Astex Therapeutics licensing deal for CDK4/6 inhibitor as a benchmark.
■
Revised SEL120 market potential. We have revised our assumptions for the potential sales of SEL120. For comparison we looked at other CDK inhibitors in the market. Pfizer’s Ibrance (palbociclib) was the first CDK4/6 inhibitor approved in February 2015 for HR+/HER2- advanced or metastatic breast cancer. According to EvaluatePharma, the drug brought $723m in sales in 2015 and $2.1bn in 2016. The consensus estimate is sales of $7.4bn by 2022. In March 2017, the US FDA approved a close competitor Kisqali (ribociclib, Novartis, consensus sales of $1.5bn in 2022), while Eli Lilly’s Verzenio (abemaciclib, consensus sales $1.8bn in 2022) was approved in September. These new drugs represent a breakthrough in the treatment of advanced breast cancer, as, for example, in Pfizer’s Phase III trial PALOMA-2 with breast cancer patients progression-free survival was 24.8 months in the Ibrance + letrozole (aromatase inhibitor) arm compared to 14.5 months in the placebo + letrozole arm. According to consensus expectations the sales of the three drugs could total $10.5bn by 2022. However, the main issues with this first generation of CDK inhibitors are the lack of selectivity within the CDK family and inhibition of other kinases leading to a variety of side effects, with bone marrow suppression and neutropenia being the main one. In general, depending on subtypes, CDKs play varied roles in the control of cell cycle, proliferation and mRNA transcription. SEL120 is a uniquely differentiated selective CDK8 inhibitor mainly regulating mRNA transcription; therefore it is not directly comparable to CKD4/6 inhibitors. We nevertheless view such a strong performance of the first wave of CDK4/6 inhibitors as indicative of a large potential within the CDK family, especially since they can be developed for a variety of solid and haematological cancers. While SEL120 is about to enter Phase I and precise indications are still not clear, we have tentatively increased our peak sales assumption for SEL120 from $750m to $1.5bn to reflect its blockbuster potential.
Exhibit 12: Selected licensing deals used as benchmarks for relevant products
Date |
Licensor |
Licensee |
Product |
Stage |
Upfront, $m |
Deal value (excl. upfront), $m |
SEL120 |
|
|
|
|
|
|
December 2005 |
Astex Therapeutics |
Novartis |
Kisqali (ribocilicb) – CDK4/6 inhibitor |
Phase I |
Undiscl. |
520 |
November 2017 |
Loxo Oncology |
Bayer |
Larotrectinib – tropomyosin receptor kinase inhibitor |
Phase 1/2 |
400 |
1,150 |
SMARCA2 inhibitor |
|
|
|
|
|
|
September 2016 |
Hanmi Pharmaceuticals |
Genetech (Roche) |
HM95573 – RAF kinase inhibitor |
Phase I |
80 |
830 |
December 2016 |
Dong-A ST |
AbbVie |
Mer TK inhibitor |
Preclin. |
40 |
485 |
A2A antagonist |
|
|
|
|
|
|
August 2015 |
Heptares |
AstraZeneca |
HTL-1071 – A2A receptor antagonist, |
Preclin. |
10 |
500 |
February 2015 |
Vernalis |
Corvus Pharmaceuticals |
CPI-444 – adenosine antagonist |
Phase I |
1 |
200 per indication |
January 2017 |
Domain Therapeutics |
Merck KGaA |
Adenosine receptor antagonists |
|
Undiscl. |
280 |
September 2017 |
Arcus Bioscience |
Taiho |
Targets likely involve CD73, CD39 and the A2A and A2B receptors. |
Preclin. |
|
$35m over 3 years $275m for each drug programme |
SHMT2 inhibitor |
|
|
|
|
|
|
April 2010, amended several times since |
Agios Pharmaceuticals |
Celgene |
AG-881 – pan-IDH mutant inhibitor AD-120 – IDH1 mutant inhibitor AG-221 – IDH2 mutant inhibitor |
|
|
70 120 120 |
Exhibit 13: Sum-of-the-parts Selvita valuation
Product |
Launch |
Peak sales, $m |
NPV (PLNm) |
NPV/sh. (PLN) |
Probability |
rNPV (PLNm) |
rNPV/sh. (PLN) |
Innovation |
|
|
|
|
|
|
|
SEL24 |
2023 |
750 |
642.6 |
46.7 |
7.5% |
74.3 |
5.4 |
SEL120 |
2025 |
1,500 |
1,346.1 |
97.7 |
10% |
153.3 |
11.1 |
SMARCA2 inhibitor |
2030 |
1,000 |
580.5 |
42.1 |
2% |
91.9 |
6.7 |
A2A/A2B antagonist |
2030 |
1,000 |
646.9 |
47.0 |
2% |
89.3 |
6.5 |
SHMT2 inhibitor |
2031 |
1,000 |
393.3 |
28.6 |
2% |
61.9 |
4.5 |
Merck collaborations |
2026 |
2,000 |
45.3 |
3.3 |
5% |
8.6 |
0.6 |
|
|
|
|
|
|
|
|
Services (incl. Ardigen) |
Market |
|
DCF (Q417-2027) |
100% |
168.8 |
12.3 |
|
|
|
Terminal value |
100% |
356.9 |
25.9 |
|
|
|
|
|
|
|
|
Net cash |
|
|
|
100% |
32.0 |
2.3 |
Valuation |
|
|
3,654.6 |
265.4 |
|
1,037.0 |
75.3 |
Source: Edison Investment Research. Note: WACC = 12.5% for product valuations, WACC = 10% for Services segment.
Exhibit 14: Assumptions for R&D projects and services business
Product / stage / indication |
Comments |
Targeted therapeutics platform |
SEL24 - Phase I/II - r/r AML |
Market potential: $750m indicative peak sales. AML treatment currently dominated largely by traditional chemotherapy drugs. Two novel drugs were approved in 2017 and the consensus expects rapid market growth (Exhibit 5) to $2.9bn in 2022 as more novel drugs are expected to be approved in coming years. R&D costs and timelines: according to the agreement, Menarini is due to take over the development by the end of 2017 and Selvita will not incur any R&D costs afterwards. We assume launch in 2023 with peak sales reached in six years. Licensing terms: Menarini deal terms include an upfront payment of €4.8m, a total of €89.1m in potential milestone payments and non-specified single- to low-double-digit royalties (we assume up to 10%) and cost sharing. Market protection: until mid-to-late 2030. |
SEL120 - IND studies - Cancer |
Market potential: $1.5bn indicative peak sales. While SEL120 (CDK8 inhibitor ) is not directly comparable to CKD4/6 inhibitors, we nevertheless view the strong the strong performance of the first CDK4/6 inhibitors (Ibrance, Kisqali and Verzenio) as indicative of a large potential within the CDK family, especially since they can be developed for a variety of solid and haematological cancers. R&D costs and timelines: $19m in R&D costs for Selvita (partly funded by LLS, see below) to develop the drug to Phase II in 2020. Then out-licensing. The partner continues the development and launches in 2027 with peak sales reached in six years. Licensing terms: According to the deal terms, LLS will provide up to $3.25m in funding over the next four years. This should allow Selvita to progress SEL120 through IND-enabling studies through to Phase I in AML. In Phase II (2020) we assume a licensing deal with terms similar to Novartis/Astex deal. Upfront was undisclosed, we use 5% of the milestone value $26m (Exhibit 12). We assume up to 15% royalty rates. Market protection: until mid-to-late 2030. |
BRM/SMARCA2 - Identification of lead compounds - Various cancer, primary indication could be NSCLC |
Market potential: Selvita has identified NSCLC with mutated SMARCA4 as clear initial target. Average sales of the top 10 drugs in NSCLC are estimated to reach $2.16bn. The target population of NSCLC is only around 8% with SMARCA4 mutations; however, there is potential that SMARCA2 inhibition would show efficacy in tumours with mutations in other proteins from SWI/SNF complex, which is 20% of all tumours thus significantly expanding the market potential. To account for the overall potential, but erring on the conservative side we use an assumption of $1bn in peak sales for Selvita’s SMARCA2 inhibitor. R&D costs and timelines: Selvita indicated that a clinical candidate could be identified in 2019, we therefore assume Phase I to start in 2021 and an out-licensing deal the same year, as the company indicated that an early partnership will be needed. R&D cost of $3m to reach Phase I. The partner continues the development and launches in 2030 with peak sales reached in six years. Licensing terms: $40m upfront and $485m in milestones split over clinical development and commercialisation. We use AbbVie/Dong-A ST deal as a benchmark from Exhibit 12. We assume 7-10% royalty rates. Market protection: we assume market protection until late 2030. |
Cancer metabolism and immunometabolism platform |
|
Merck deals #1 and #2 - Preclinical - cancer |
Technology remains undisclosed. Assume two projects in Phase I in 2020 with launch in 2028 and peak sales of $1bn in each project in 2034. Licensing fee €0.2m; total milestone payments could add up to €16.5m in each deal. Royalties have not been disclosed, we assume up to 2%. |
A2A/A2B antagonist - Identification and optimization of lead compound - Various cancers |
Market potential: Selvita believes the relevant target populations could be broad with the immunosuppressive environment prevalent in around 50% of all cancers. There is also a strong rationale for synergistic potential with checkpoint inhibitors. Because checkpoint inhibitors have gained widespread recognition, but suffer from non-responder issues, combination treatments are likely the future of immunooncology. Because of the lack of detail about potential specific indications, but to reflect the broad potential, we use $1bn as our peak sales assumption. R&D costs and timelines: We assume that a clinical candidate could be identified in 2018 and partnered in 2019. We assume an R&D cost of $2m for Selvita to develop the asset to partnership deal. Phase I to start in 2021 and the partner continues the development and launches in 2030 with peak sales reached in six years. Licensing terms: We use the Heptares/AstraZeneca deal as a benchmark. $10m upfront and $500m in milestones split over clinical development and commercialisation. We assume 7-10% royalty rates. Market protection: we assume market protection until late 2030. |
SHMT2 inhibitor - Identification and optimization of lead compound - Various cancers |
Market potential: Overactivation of serine synthesis pathway and upregulation of SHMT has been described in over 20% of solid tumours therefore, while it is still not clear what could be primary indications, the potential seems wide. As in the case of A2A/A2B antagonist, we assume $1bn in peak sales. R&D costs and timelines: We assume that a clinical candidate could be identified in 2018/19 and partnered in 2020. We assume the R&D cost for Selvita to develop the asset to partnership deal is $3m. Phase I to start in 2022 and the partner continues the development and launches in 2031 with peak sales reached in six years. Licensing terms: We use the value of Agios/Celgene deals involving three separate products, but all focusing on isocitrate dehydrogenasemutant (IDH) mutant inhibitors. $10m upfront and $310m in milestone payments split over clinical development and commercialisation. We assume 7-10% royalty rates. Market protection: we assume market protection until late 2030. |
|
Drug discovery services collaborations |
Services: sliding scale pa growth from c 25% in 2018 to 12% in 2027; research collaborations: +10-5% pa growth to 2027; subsidies: +5-3% pa growth; tax = 2-11% sliding scale (2017-27); 10% WACC. For terminal value calculation we use 0.75% growth on 2025 FCF. |
Source: Edison Investment Research.
Selvita’s 9M17 total revenues were PLN80.5m, up by impressive 65% y-o-y. Commercial revenues (ie excluding subsidies/grants) were PLN68.9m, up 70%, while subsidies (allocated to both the Innovation and Services segments) accounted for PLN11.6m, up 41%. Total 9M17 operating expenses (excluding ESOP costs) increased to PLN68.7m from PLN45.2m, as Selvita has been growing its staff count and has opened new facilities in Poznan as well as new international sales offices. The 9M17 operating margin, however, increased to 15% from 8% a year ago, boosted by the Menarini deal. Selvita reported 9M17 capex (tangible and intangible) of PLN15.1m versus PLN10.6m a year ago reflecting mainly organic growth. Selvita’s new strategy provided more details about the funding sources for the first stage of capacity expansion (page 15). We have already included that in our model and for the time being maintain our approach and assume that this will be funded using debt. Selvita reported cash of PLN37m in November and had PLN5.1m in debt.
Segment performance
Commercial revenues from the Innovation segment grew 118% to PLN32.7m in 9M17. The segment’s 9M17 net profit was PLN7.3m, up from PLN3.5m a year ago. Notably, Innovation includes Selvita’s own R&D pipeline activities so developing it is a long-term strategic goal. Commercial revenues from this segment come from payments related to different partnerships, such as milestone payments from drug discovery collaborations, and therefore tend to be volatile from quarter to quarter, but offer potentially higher margins. The out-licensing of SEL24 to Menarini is the main reason for such a strong performance this year (deal details described on page 5). The upfront payment was PLN20.3m, but because Selvita has capitalised certain costs associated with SEL24 development, the profit booked in the P&L was PLN13m. Selvita will also receive milestone payments if the development of SEL24 is successful.
The profitability-driving Services segment reached 9M17 sales of PLN30.5m (excluding subsidies), an increase of 31% y-o-y, which reflects solid organic services business growth. The segment’s net profit was PLN2.9m compared to PLN567k a year ago. Business portfolio expansion, entering new markets and an increasing number of FTE and integrated contracts were the growth drivers indicated by Selvita.
While a small business on an absolute basis (5.0% of total Selvita revenues in FY16) the Bioinformatics (Ardigen) segment has been a positive surprise to us since the spinout in October 2015 (Selvita has 51%, consolidates the accounts and reports as a third business segment). 9M17 sales were PLN5.3m, a 159% increase versus a year ago.
Record backlog for 2017
Together with its Q317 results, Selvita reported a record order backlog of PLN100.4m for this year. Exhibit 15 provides a breakdown of the backlog per sector and comparison to end-year sales. Backlogs of all three business segments, including subsidies (which are allocated to segments), have increased substantially year-on-year, with Innovation and Bioinformatics leading. We expect sales of PLN106m and PLN99m in 2017 and 2018 respectively. The large up-front payment from Menarini is the main reason for our flattish forecast in 2018. Notably, we do not include in our financial forecasts any subsequent milestone payments from Menarini, as Selvita did not provide any guidance, so the visibility is low (we include risk-adjusted milestones in our rNPV model).
On the cost side, Selvita presented a breakdown of expected investments associated with its new strategy for 2017-2021. As mentioned (page 3) Selvita’s preliminary estimate is a total investment of around PLN360m financed from internal reserves, public grants, bank loans and a planned share issue (PLN140m). As the green light for the share issue depends on the outcome from the interactions with the FDA, we do not include this in our model. Of the total amount, the company expects PLN260m will be used for the development of the internal R&D pipeline. This translates roughly to PLN65m per year for the next four years and means a substantial ramp up in R&D activities. For comparison, costs associated with the Innovation segment were PLN36m in 9M17. At present we have not revised our estimates to fully reflect the new investment plans, but we do anticipate a pick-up in R&D spend, especially with SEL120 as the company plans to initiate a Phase I trial next year. We therefore forecast break-even on operating profit in FY18. Once all funding sources are in place and more details emerge about the ongoing R&D activities, we will look to revise our estimates.
Exhibit 15: Backlog and year-end sales
|
|
Source: Selvita’s accounts
|
Exhibit 16: Financial summary
|
|
PLN'000s |
2013 |
2014 |
2015 |
2016 |
2017e |
2018e |
Year end 31 December |
|
|
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
PROFIT & LOSS |
|
|
|
|
|
|
|
|
Revenue |
|
|
21,914 |
41,557 |
56,077 |
66,721 |
105,994 |
99,167 |
of which: Services (research outsourcing) |
|
9,812 |
16,121 |
23,052 |
32,404 |
43,746 |
54,682 |
Innovation platform |
|
|
3,241 |
12,744 |
15,416 |
18,353 |
38,638 |
20,189 |
Subsidies |
|
|
8,688 |
12,430 |
14,700 |
12,067 |
16,290 |
16,290 |
Bioinformatics |
|
|
|
|
2,561 |
3,431 |
6,855 |
7,541 |
EBITDA |
|
|
(146) |
7,626 |
10,235 |
8,264 |
17,915 |
5,770 |
Operating Profit (before GW and except.) |
|
(2,228) |
5,272 |
6,802 |
4,646 |
13,212 |
1,067 |
Intangible Amortisation |
|
|
0 |
0 |
0 |
0 |
0 |
0 |
Exceptionals/Other* |
|
|
0 |
0 |
(4,729) |
(5,860) |
(583) |
0 |
Operating Profit |
|
|
(2,228) |
5,272 |
2,073 |
(1,214) |
12,629 |
1,067 |
Net Interest |
|
|
(198) |
155 |
748 |
947 |
(1,050) |
20 |
Share in profit/(loss) of asocs. and JVs** |
|
0 |
0 |
0 |
(1,016) |
(808) |
(808) |
Other |
|
|
0 |
0 |
0 |
0 |
0 |
0 |
Profit Before Tax (norm) |
|
|
(2,427) |
5,427 |
7,550 |
4,577 |
11,354 |
279 |
Profit Before Tax (reported) |
|
|
(2,427) |
5,427 |
2,821 |
(1,283) |
10,771 |
279 |
Tax |
|
|
(19) |
(45) |
(5) |
0 |
(323) |
(14) |
Deferred tax |
|
|
0 |
468 |
3,417 |
3,968 |
0 |
0 |
Profit After Tax (norm) |
|
|
(2,445) |
5,850 |
10,962 |
8,545 |
11,031 |
265 |
Profit After Tax (reported) |
|
|
(2,445) |
5,850 |
6,233 |
2,685 |
10,448 |
265 |
|
|
|
|
|
|
|
|
|
Average Number of Shares Outstanding (m) |
|
10.5 |
10.5 |
13.1 |
13.4 |
13.6 |
13.6 |
EPS - normalised (PLN) |
|
|
(0.23) |
0.56 |
0.84 |
0.64 |
0.81 |
0.02 |
EPS - reported (PLN) |
|
|
(0.23) |
0.56 |
0.48 |
0.20 |
0.77 |
0.02 |
Dividend per share (PLN) |
|
|
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
|
|
|
|
|
|
|
|
BALANCE SHEET |
|
|
|
|
|
|
|
|
Fixed Assets |
|
|
7,067 |
9,494 |
16,718 |
41,451 |
46,543 |
85,140 |
Intangible Assets |
|
|
282 |
331 |
2,274 |
6,640 |
435 |
435 |
Tangible Assets |
|
|
4,932 |
6,845 |
8,597 |
21,833 |
33,130 |
71,727 |
Other |
|
|
1,854 |
2,318 |
5,847 |
12,979 |
12,979 |
12,979 |
Current Assets |
|
|
11,191 |
17,310 |
48,524 |
47,669 |
60,692 |
49,882 |
Stocks |
|
|
391 |
706 |
1,174 |
1,403 |
1,384 |
1,365 |
Debtors |
|
|
5,161 |
10,314 |
17,961 |
16,320 |
16,320 |
16,320 |
Cash |
|
|
5,418 |
4,878 |
28,807 |
29,095 |
40,688 |
29,897 |
Other |
|
|
221 |
1,411 |
582 |
851 |
2,300 |
2,300 |
Current Liabilities |
|
|
(11,401) |
(15,271) |
(16,319) |
(18,933) |
(23,665) |
(23,355) |
Creditors |
|
|
(3,481) |
(6,055) |
(3,927) |
(7,883) |
(9,400) |
(9,400) |
Provisions |
|
|
(2,104) |
(2,801) |
(3,327) |
(3,600) |
(6,650) |
(6,650) |
Deferred revenues |
|
|
(5,455) |
(4,617) |
(7,384) |
(5,469) |
(5,069) |
(5,069) |
Short term borrowings |
|
|
(161) |
(91) |
(33) |
(859) |
(950) |
(950) |
Other |
|
|
(200) |
(1,708) |
(1,648) |
(1,122) |
(1,595) |
(1,286) |
Long Term Liabilities |
|
|
(3,454) |
(2,278) |
(2,043) |
(14,477) |
(13,728) |
(38,728) |
Long term borrowings |
|
|
0 |
0 |
0 |
(4,792) |
(4,200) |
(29,200) |
Deferred revenues |
|
|
(3,222) |
(2,010) |
(1,513) |
(6,382) |
(6,700) |
(6,700) |
Other long term liabilities |
|
|
(232) |
(268) |
(529) |
(3,303) |
(2,828) |
(2,828) |
Net Assets |
|
|
3,403 |
9,254 |
46,880 |
55,710 |
69,843 |
72,939 |
|
|
|
|
|
|
|
|
|
CASH FLOW |
|
|
|
|
|
|
|
|
Operating Cash Flow |
|
|
(7,198) |
(4,902) |
(16,430) |
(6,280) |
12,176 |
(8,459) |
Net Interest |
|
|
0 |
0 |
0 |
0 |
0 |
0 |
Tax |
|
|
0 |
0 |
0 |
0 |
0 |
(323) |
Capex |
|
|
(2,167) |
(3,610) |
(5,190) |
(21,210) |
(16,000) |
(43,300) |
Acquisitions/disposals |
|
|
0 |
0 |
0 |
0 |
0 |
0 |
Financing |
|
|
0 |
0 |
27,314 |
303 |
328 |
0 |
Dividends |
|
|
0 |
0 |
0 |
0 |
0 |
0 |
Other (incl. subsidies) |
|
|
9,567 |
7,972 |
18,354 |
21,859 |
15,590 |
16,290 |
Net Cash Flow |
|
|
202 |
(540) |
24,049 |
(5,329) |
12,094 |
(35,791) |
Opening net debt/(cash) |
|
|
(5,192) |
(5,257) |
(4,787) |
(28,773) |
(23,445) |
(35,538) |
HP finance leases initiated |
|
|
0 |
0 |
0 |
0 |
0 |
0 |
Exchange rate movements |
|
|
0 |
0 |
0 |
0 |
0 |
0 |
Other |
|
|
(137) |
71 |
(63) |
1 |
(1) |
0 |
Closing net debt/(cash) |
|
|
(5,257) |
(4,787) |
(28,773) |
(23,445) |
(35,538) |
253 |
Source: Edison Investment Research, Selvita accounts. Note: *Non-cash cost related to the employee stock options programme. **Profit and loss from 2016 include share in Nodthera’s earnings according to an equity method valuation. Please note that the share changed in 2017 as a result of Nodthera's capital increase.
Contact details |
Revenue by geography (2016) |
Park Life Science ul. Bobrzyńskiego 14 30-348 Kraków Poland +48 12 297 47 00 www.selvita.com |
|
Contact details |
Park Life Science ul. Bobrzyńskiego 14 30-348 Kraków Poland +48 12 297 47 00 www.selvita.com |
Revenue by geography (2016) |
|
Management team |
|
Chief executive officer (co-founder): Paweł Przewięźlikowski |
Chief operating officer (co-founder): Bogusław Sieczkowski |
Paweł Przewięźlikowski co-founded Selvita in 2007. From 1994 to 2007 he worked at Comarch, a Polish information technology company, becoming VP on the management board in 1996. While at Comarch, he was also the co-founder and the first CEO of Interia.pl, the third largest portal in Poland. He holds an MBA and MSc in information technology. |
Bogusław Sieczkowski co-founded Selvita in 2007. From 2001 to 2007 he was VP and sub-section director at Comarch. Previously he was IT manager at Bahlsen Polska (1995-99). He holds an MBA and MSc in information technology. |
Chief scientific officer: Krzysztof Brzózka |
Director of chemistry department: Mirosława Zydroń |
Krzysztof Brzózka joined Selvita in 2007, became project manager (oncology compound) in 2009 and was appointed CSO in 2012. From 2003 to 2007 Krzysztof worked on a broad immunology research programme at Ludwig Maximillian University (Munich). He holds a PhD (molecular biology), an MSc and an MBA. |
Mirosława Zydroń joined Selvita in 2009 and was appointed to the management board in 2013. From 2005 to 2009 Mirosława held various roles at Pliva (now Teva), including head of the R&D laboratory. She holds a PhD (analytical chemistry), an MSc and an MBA. |
Director of biology department: Miłosz Gruca, PhD |
|
Miłosz Gruca was appointed director of biology in 2010 (appointed to the management board in 2012), having worked at Selvita and BioCentrum (a Selvita subsidiary) since 2007, responsible for the introduction of complex biological and analytical services at Selvita. He holds a PhD (biochemistry), an MSc and an MBA. |
|
Management team |
Chief executive officer (co-founder): Paweł Przewięźlikowski |
Paweł Przewięźlikowski co-founded Selvita in 2007. From 1994 to 2007 he worked at Comarch, a Polish information technology company, becoming VP on the management board in 1996. While at Comarch, he was also the co-founder and the first CEO of Interia.pl, the third largest portal in Poland. He holds an MBA and MSc in information technology. |
Chief operating officer (co-founder): Bogusław Sieczkowski |
Bogusław Sieczkowski co-founded Selvita in 2007. From 2001 to 2007 he was VP and sub-section director at Comarch. Previously he was IT manager at Bahlsen Polska (1995-99). He holds an MBA and MSc in information technology. |
Chief scientific officer: Krzysztof Brzózka |
Krzysztof Brzózka joined Selvita in 2007, became project manager (oncology compound) in 2009 and was appointed CSO in 2012. From 2003 to 2007 Krzysztof worked on a broad immunology research programme at Ludwig Maximillian University (Munich). He holds a PhD (molecular biology), an MSc and an MBA. |
Director of chemistry department: Mirosława Zydroń |
Mirosława Zydroń joined Selvita in 2009 and was appointed to the management board in 2013. From 2005 to 2009 Mirosława held various roles at Pliva (now Teva), including head of the R&D laboratory. She holds a PhD (analytical chemistry), an MSc and an MBA. |
Director of biology department: Miłosz Gruca, PhD |
Miłosz Gruca was appointed director of biology in 2010 (appointed to the management board in 2012), having worked at Selvita and BioCentrum (a Selvita subsidiary) since 2007, responsible for the introduction of complex biological and analytical services at Selvita. He holds a PhD (biochemistry), an MSc and an MBA. |
|
|
Principal shareholders |
(%) |
Paweł Przewięźlikowski (co-founder, CEO) |
36.2 |
Tadeusz Wesołowski |
8.2 |
Nationale Nederlanden PTE S.A. |
6.9 |
Bogusław Sieczkowski |
6.7 |
|
Companies named in this report |
Merck KGaA; H3 Biomedicine (Eisai), Merck & Co, Novartis, AstraZeneca, Incyte, Ambit Biosciences (Daiichi Sankyo), Astellas Pharma, Arog Pharma, Strategia Therapeutics, Takeda |
|
Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt and Sydney. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com DISCLAIMER Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Selvita and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Investments Pty Ltd (Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd (AFSL: 427484)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited (“FTSE”) © FTSE 2017. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent. |
Frankfurt +49 (0)69 78 8076 960 Schumannstrasse 34b 60325 Frankfurt Germany |
London +44 (0)20 3077 5700 280 High Holborn London, WC1V 7EE United Kingdom |
New York +1 646 653 7026 245 Park Avenue, 39th Floor 10167, New York US |
Sydney +61 (0)2 9258 1161 Level 25, Aurora Place 88 Phillip St, Sydney NSW 2000, Australia |
Frankfurt +49 (0)69 78 8076 960 Schumannstrasse 34b 60325 Frankfurt Germany |
London +44 (0)20 3077 5700 280 High Holborn London, WC1V 7EE United Kingdom |
New York +1 646 653 7026 245 Park Avenue, 39th Floor 10167, New York US |
Sydney +61 (0)2 9258 1161 Level 25, Aurora Place 88 Phillip St, Sydney NSW 2000, Australia |
|
Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt and Sydney. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com DISCLAIMER Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Selvita and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Investments Pty Ltd (Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd (AFSL: 427484)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited (“FTSE”) © FTSE 2017. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent. |
Frankfurt +49 (0)69 78 8076 960 Schumannstrasse 34b 60325 Frankfurt Germany |
London +44 (0)20 3077 5700 280 High Holborn London, WC1V 7EE United Kingdom |
New York +1 646 653 7026 245 Park Avenue, 39th Floor 10167, New York US |
Sydney +61 (0)2 9258 1161 Level 25, Aurora Place 88 Phillip St, Sydney NSW 2000, Australia |
Frankfurt +49 (0)69 78 8076 960 Schumannstrasse 34b 60325 Frankfurt Germany |
London +44 (0)20 3077 5700 280 High Holborn London, WC1V 7EE United Kingdom |
New York +1 646 653 7026 245 Park Avenue, 39th Floor 10167, New York US |
Sydney +61 (0)2 9258 1161 Level 25, Aurora Place 88 Phillip St, Sydney NSW 2000, Australia |
|